GOP senators distance themselves from Grassley, Trumps efforts to cut drug prices

Fiercepharma | July 26, 2019

GOP senators distance themselves from Grassley, Trumps efforts to cut drug prices
The fight between policymakers intent on lowering prescription drug prices and the drugmakers who keep raising them intensified Thursday as a slew of Republican senators threatened to side with manufacturers against legislation supported by their own committee chairman and president. After months of closed-door meetings and high-profile hearings, the Senate Finance Committee voted 19-9 to advance legislation introduced by Sens. Chuck Grassley, R-Iowa, and Ron Wyden, D-Oregon, to rein in drug costs in the Medicare and Medicaid programs. But even some Republicans who supported it warned they may not back the sweeping package of proposals in a full Senate vote. They object in particular to a provision that would cap drug prices paid by Medicare based on the rate of inflation. Other obstacles have piled up. Wyden announced that Democrats, who provided most of the bill’s support in committee, would not allow a Senate vote without the Republicans agreeing to hold votes on cementing insurance protections for people with preexisting conditions. Democrats have complained for months that GOP efforts to kill the Affordable Care Act (ACA) will leave people with these medical problems without any recourse to get affordable healthcare. Democrats also want to empower federal health officials to negotiate drug prices.

Spotlight

Since eyeforpharma, Barcelona 2015, we have heard industry, vendors, specialists, advocacy groups and patients talking about patient-centricity: what is it? What does it mean for the industry and the wider healthcare environment? What does it mean for patients? What will it look like in the future.

Related News

Pharma sees more post-M&A rebrands than other industries—and it does them better, too

Fiercepharma | June 03, 2020

To rebrand or not? It’s a big question for pharma companies before and after acquisitions—and one answered with "yes" more often than in other industries. Pharma, in fact, was the most prolific rebrander in Brand Finance’s recent research assessing the value of rebrands across 25 industries. It's also one of the most successful, with rebrands in pharma generating average returns of 13.8%, according to Brand Finance calculations. The main reason? Most acquired pharma brands are weaker than the acquiring ones, the study found. Pharma rebranded 31% of the companies acquired in deals during the five-year study period beginning Jan. 2014 and ending Dec. 2018. That figure was just ahead of the healthcare (30%), telecom (29%) and oil and gas (25%) industries. The study assessed all deals valued at $500 million or more.

Read More

PHARMA TECH

Phanes Therapeutics reveals SPECpair™ technology platform that enhances manufacturability of bispecific antibodies

Phanes Therapeutics | September 13, 2021

Phanes Therapeutics, Inc., an emerging leader in innovative drug discovery research and development in immuno-oncology announced today that it has developed a proprietary technology platform, SPECpair™, which enables the use of the conventional monoclonal antibody (mAb) manufacturing process in the production of native IgG-like bispecific antibodies. This is the third technology platform Phanes has developed since the launch of the PACbody™ and ATACCbody™ platforms, which are designed to construct bispecific antibodies with native IgG-like structures and modulated activities, respectively. "SPECpair™ represents a milestone where we have brought our innovative research to the process development and manufacturing space. This technology solves a huge and common problem in manufacturing bispecific antibodies with native IgG-like structures," said Dr. Hui Zou, PhD, Chief Scientific Officer (CSO) of Phanes Therapeutics. "Phanes is an emerging leader in innovative drug research in biologics aimed at targeting various cancers. In the span of only a few years, we have built not only a differentiated pipeline but also three technology platforms. Our technology platforms solve important problems in both the research and manufacturing steps. I believe we are in a very strong position to leverage these technologies to advance our own pipeline and help advance the innovation of others in our industry," said Ming Wang, PhD/MBA, CEO of Phanes Therapeutics, "At Phanes, our mission is to become a source of innovation in the biopharma industry and we are fully committed to expanding the reach of our innovation by building partnerships with various pharma and biotech companies."

Read More

Cannabis Industry Giant WayofLeaf.com Expands Health-Specific Content, Introduces Medical Review Team

Prnewswire | September 30, 2020

In a bid to improve the quality and availability of information on health-specific cannabis use, industry giant WayofLeaf.com has introduced a team of doctors and health experts to review thousands of topics relating to the use of medical cannabis and CBD for specific health conditions. The website, which for years has provided a reliable informational resource for medical cannabis patients, believes it is time for cannabis users of all types to have access to trustworthy, research-backed content on specific conditions and ailments. "There's no shortage of information out there in terms of using cannabis medicinally," says WayofLeaf Medical Director Dr. Lynn Marie Morski. "However there is a need for more trustworthy, research-backed information that medical cannabis and CBD users can rely on."

Read More

Spotlight

Since eyeforpharma, Barcelona 2015, we have heard industry, vendors, specialists, advocacy groups and patients talking about patient-centricity: what is it? What does it mean for the industry and the wider healthcare environment? What does it mean for patients? What will it look like in the future.